Efavirenz-Induced Decrease in Plasma Amprenavir Levels in Human Immunodeficiency Virus-Infected Patients and Correction by Ritonavir
- 1 September 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (9) , 2593
- https://doi.org/10.1128/aac.44.9.2593-2593.2000
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected AdultsAntimicrobial Agents and Chemotherapy, 1999
- RitonavirClinical Pharmacokinetics, 1998
- EfavirenzDrugs, 1998
- AmprenavirDrugs, 1998
- Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus TherapyThe Journal of Infectious Diseases, 1995